CurrentCignaPolicy 0103

Gastric Pacing / Gastric Electrical Stimulation (GES)

Defines Cigna coverage for permanent and temporary gastric electrical stimulation devices for treatment of intractable nausea and vomiting secondary to gastroparesis and states coding and FDA contextual information; applies to services under Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyGastric Pacing / Gastric Electrical Stimulation (GES)

Policy CodePolicy 0103

Change TypeAnnual review — no policy statement changes

Effective DateNov 15, 2025

Next Review DateNov 15, 2026

Key ActionObtain prior authorization and document prior failure, contraindication, or intolerance of pharmacologic therapy before permanent GES is approved.

SourceLink

POLICY UPDATE CHANGES

No clinical policy statement changes were made during the annual review dated 11/15/2025.

The gastric electrical stimulation (GES) or gastric pacing for any other indication policy statement was revised during the annual review dated 10/15/2023.

Refractory nausea/vomitingPrimary covered indication

HDEFDA approval pathway

7 codesCovered codes (when criteria met)

2 codesExperimental codes (tGES)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Annual review outcome

Coverage Criteria and Policy Statements

inv-01: Permanent GES (medically necessary)

Covered when ALL of the following are met:

Permanent GES (medically necessary): 1) Device is a permanent gastric electrical stimulation/gastric pacing system (e.g., Enterra Therapy) provided in accordance with the FDA Humanitarian Device Exemption (HDE) specifications (HDE Number: H990014); 2) The clinical indication is chronic, intractable (drug‑refractory) nausea and vomiting secondary to gastroparesis (diabetic or idiopathic etiologies) as described in the HDE; 3) The patient has documented failure, contraindication, or intolerance to appropriate pharmaceutical therapy for gastroparesis (e.g., prokinetics and antiemetics) and optimization of medical management; 4) Device use is consistent with any applicable device labeling regarding the typical age range (eg, adults 18–70) and other HDE‑specified population considerations.

Coverage is limited to HDE‑specified use and populations; effectiveness for other etiologies or age groups has not been established.

inv-02: Temporary GES

Not covered / investigational

Temporary GES stance: Temporary gastric electrical stimulation (tGES), including endoscopic or percutaneous temporary lead approaches, is considered experimental, investigational, or unproven and is not covered; FDA approval for temporary GES was not found and temporary approaches represent off‑label use.

Claims for temporary GES are frequently reported with unlisted stomach procedure codes (eg, 43659, 43999) which the policy lists as experimental/investigational.

inv-03: Other indications

Not covered

Non-gastroparesis indications: Gastric electrical stimulation or gastric pacing for any indication other than intractable nausea and vomiting secondary to gastroparesis is not covered or reimbursable.

Examples explicitly identified as not covered or investigational include obesity and type 2 diabetes mellitus.

inv-04: GES for Obesity

Evidence and trial results for GES in obesity and type 2 diabetes — summary of findings

Obesity indication evidence: Published evidence for GES as a treatment for obesity includes case series, cohort studies, randomized trials and systematic reviews with generally low quality, small sample sizes, and inconsistent long‑term benefit. Some studies (eg, phase‑1 Exilis cohort) showed short‑term weight loss with mean excess weight loss ~14.2% at 52 weeks but without significant differences in gastric emptying or food intake; the SHAPE randomized trial (n=190) did not demonstrate a statistically significant difference in excess weight loss at 12 months. Device‑related complications such as gastric penetration and IPG‑pocket issues have been reported. Overall, the FDA registers GES for obesity as investigational and current evidence is insufficient to support routine use for morbid obesity.

Well‑designed RCTs with larger populations and long‑term follow‑up are needed; see SHAPE and systematic review findings.

inv-05: GES for Type 2 Diabetes Mellitus

GES for T2DM is investigational with limited case series data

T2DM indication evidence: Evidence for GES in patients with type 2 diabetes mellitus is limited to small case series and preliminary studies (sample sizes range ~14–61) with short follow‑up (typically 6–12 months). Preliminary results suggest possible improvements in glycemic control and weight for investigational devices (eg, DIAMOND/Tantalus), but robust randomized controlled trial data are lacking and current evidence is insufficient to establish effectiveness.

Additional well‑designed RCTs are needed to confirm preliminary findings.

inv-06: Guideline Positions

Professional society positions

Guideline recommendations: American College of Gastroenterology (ACG): may be considered humanitarian for refractory diabetic or idiopathic gastroparesis; American Diabetes Association (ADA): data are very limited and do not support GES as an effective therapy in diabetic gastroparesis; American Gastroenterological Association (AGA): conditional recommendation against routine initial use, reserving GES for select refractory cases after optimized medical therapy. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): may be effective for some people whose nausea and vomiting do not improve with dietary changes or medications.

Guideline positions emphasize limited evidence and recommend GES only for select, refractory patients after optimized medical therapy.

GES or gastric pacing is covered only when used for intractable nausea and vomiting secondary to gastroparesis in accordance with the FDA Humanitarian Device Exemption (HDE) specifications (e.g., Enterra Therapy) and after failure, contraindication, or intolerance of appropriate pharmacologic therapy. Use of GES for any other indication is not covered or reimbursable; evidence for non-gastroparesis indications is limited and inconsistent, and routine coverage is not supported.

GES for morbid obesity is considered investigational and is registered by the FDA as investigational; published studies are generally small, short-term, and of low quality, and there is insufficient evidence to support routine clinical use of GES for obesity. Providers should not expect coverage for GES when the primary indication is morbid obesity.

The annual policy review dated 11/15/2025 did not result in any clinical policy statement changes regarding gastric electrical stimulation or gastric pacing; the existing coverage stance and exclusions remain in effect as of that review.

Temporary gastric electrical stimulation (tGES), including endoscopic or percutaneous temporary lead approaches, is considered experimental, investigational, or unproven and is not medically necessary. Claims for temporary GES frequently use unlisted stomach procedure codes (e.g., 43659, 43999), which are considered experimental when used for tGES and may be denied.

Randomized trials and systematic reviews of GES for weight loss have not demonstrated consistent, durable benefit. For example, the SHAPE randomized, double-blinded, placebo-controlled trial (n=190) found no statistically significant difference in excess weight loss at 12 months versus control, and a systematic review (Cha et al., 2014; n=31 studies/1,367 patients) reported short-term weight loss in many studies but concluded overall evidence quality was low with inconsistent long-term maintenance. These findings do not support routine use of GES for obesity.

Procedure and Billing Codes

Considered medically necessary codes when criteria metmixedCovered

43881	Implantation or replacement of gastric neurostimulator electrodes, antrum, open
64590	Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct or inductive coupling
C1767	Generator, neurostimulator (implantable), nonrechargeable
C1778	Lead, neurostimulator (implantable)
L8679	Implantable neurostimulator, pulse generator, any type
L8680	Implantable neurostimulator electrode, each
L8688	Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension

Considered experimental/investigational/unproven when used to report temporary GESCPTExperimental

43659	Unlisted laparoscopy procedure, stomach
43999	Unlisted procedure, stomach

FDA HDE affected population threshold (regulatory context)

FDA HDE annual affected population thresholdFewer than 8,000 individuals annually in the U.S.

HDE pathway implicationsHDE applications are not required to demonstrate effectiveness via scientifically valid clinical investigations but must show that probable benefits outweigh risks and device does not pose unreasonable risk.

Typical FDA age range in Enterra indicationAdults 18-70 years (per HDE labeling)

Provider Requirements, Prior Authorization, and Billing Guidance

Prior Authorization

Prior Authorization Required

Prior authorization is required for permanent gastric electrical stimulation (GES) when provided for intractable nausea and vomiting secondary to gastroparesis and when the intervention meets the FDA Humanitarian Device Exemption (HDE) specifications and medical necessity criteria (including documentation of pharmaceutical therapy failure, contraindication, or intolerance). Providers should submit prior authorization requests to the plan for review before implantation.

Prior authorization required for permanent GES (no procedure codes specified in this section).
Medical necessity must align with FDA HDE indication for intractable, drug‑refractory nausea and vomiting due to gastroparesis.

Prior Authorization

Prior Authorization Recommended for Investigational Indications

Prior authorization is recommended for requests to use GES for investigational indications (e.g., obesity, type 2 diabetes mellitus). These indications are considered investigational/under investigation and lack sufficient evidence to support routine coverage.

GES for obesity and T2DM: investigational — document insufficiency of evidence and provide clinical rationale if requesting review.

Clinical Background and Context

Gastroparesis is a chronic gastric motility disorder characterized by delayed gastric emptying in the absence of mechanical obstruction and commonly presents with nausea, vomiting, early satiety, bloating, and weight loss. Initial management emphasizes dietary modification and pharmacologic therapy (prokinetics and antiemetics); for patients with persistent, refractory symptoms despite optimized medical therapy, implanted high-frequency/low-energy gastric electrical stimulation systems (e.g., Enterra) have been used to reduce nausea and vomiting.

Device and Regulatory Definitions

Enterra Therapy System / GES — device description and FDA HDE context

Device typeHigh-frequency/low-energy implanted gastric neurostimulator (e.g., Enterra Therapy) delivering short-pulse stimulation to gastric musculature.

ComponentsImplanted neurostimulator (pulse generator) and intramuscular leads placed in the gastric antrum.

FDA regulatory statusClass III device regulated under Humanitarian Device Exemption (HDE H990014).

Intended clinical effectProposed to reduce symptoms of gastroparesis (nausea and vomiting) and improve gastric emptying by delivering stimulation at ~12 cycles per minute.

Temporary GES (tGES) — definition and note about regulatory status

DefinitionTemporary GES (tGES) uses non-permanent endoscopic or percutaneous leads connected to an external stimulator for short-term gastric stimulation trials.

Policy Revision History

2025-11-15annual reviewLatest

Annual review completed; no clinical policy statement changes were made.

2024-12-15annual review

Annual review completed; no clinical policy statement changes were made.

2023-10-15annual review - revised

Policy Summary

PayerCigna

PolicyGastric Pacing / Gastric Electrical Stimulation (GES)

Policy CodePolicy 0103

Change TypeAnnual review — no policy statement changes

Effective DateNov 15, 2025

Next Review DateNov 15, 2026

Key ActionObtain prior authorization and document prior failure, contraindication, or intolerance of pharmacologic therapy before permanent GES is approved.

SourceLink

On This Page

Temporary GES is considered experimental, investigational or unproven and is at high risk for denial.

Note

Prior Authorization Governance Note

Prior authorization processes and requirements are described in this policy, but specific billing or procedure codes applicable to prior authorization may be listed elsewhere in coding sections or payer guidance. Providers must follow the payer's prior authorization submission requirements.

Policy describes prior authorization governance; codes for prior auth may be specified in Coding Information or external billing guidance.
Follow standard prior authorization submission procedures of the payer.

Documentation Required

Medication Failure / Therapy Prerequisite

Before permanent GES implantation, providers must document prior failure, contraindication, or intolerance to appropriate pharmaceutical therapy (e.g., prokinetics, antiemetics). Documentation of optimization of medical management and other less invasive measures should be included in the prior authorization submission.

Document trials of, and response to, prokinetic agents (e.g., metoclopramide, erythromycin) and antiemetics, or state contraindication/intolerance.
Include evidence of dietary modification and other conservative management where applicable.

Billing Rule

Coding and Documentation Requirements

Providers should submit appropriate procedure and diagnosis codes and include supporting clinical documentation with prior authorization and claims. Claims submitted without covered codes or without required documentation may be denied as not covered.

Use the most appropriate and current CPT/HCPCS/ICD‑10 codes for the date of service.
Claims for services reported with unlisted codes or codes that do not align with covered indications may be denied.

Documentation Required

Typical Study and Clinical Documentation Elements

Typical documentation to support GES coverage decisions includes patient BMI (when relevant), comorbidities, symptom severity and duration, objective measures (e.g., gastric emptying studies), HbA1c for diabetes evaluations, details of prior medical therapies tried and failed, and description of the perioperative course and device implanted.

Include BMI, comorbid conditions, HbA1c (if evaluating T2DM), gastric emptying study results, and duration/severity of symptoms.
Detail prior medical treatments tried (medications, dietary therapy, feeding tubes, TPN) and the perioperative device and course.

Denial Risk

Denial Risks for Temporary or Non‑Covered Indications

Claims for temporary GES or for GES used for non‑covered or experimental indications are at high risk for denial. Providers should avoid billing permanent-implant codes for temporary or investigational uses and be aware that unlisted procedure codes for such services are frequently considered experimental/unproven.

Temporary GES is considered experimental/unproven — billing may be denied.
Services billed with unlisted codes for non‑covered indications are likely to be denied.

Note

Alignment with Professional Guidelines

Professional guidelines reserve GES as a consideration for select patients with refractory gastroparesis after optimization of medical therapy. Providers should align prior authorization requests with guideline recommendations and document that symptoms remained refractory despite optimized care.

ACG/AGA/ADA guidance: GES may be considered for humanitarian use or reserved for select refractory patients after optimized therapy and shared decision‑making.
Document efforts at optimized medical therapy and rationale for device consideration.

Note

Clinical Literature and Supporting References

Clinical literature cited in this policy includes observational studies, case series, a limited number of randomized trials, and device resources that inform expectations for efficacy, safety, and documentation. These references may guide the stepwise approach and evidence included in prior authorization submissions.

Key literature examples: long‑term observational studies and prospective trials (see references 39–60).
Evidence base is limited — mainly observational data and small RCTs; include relevant literature when submitting for investigational requests.

Note

Medicare Coverage Determinations

No National or Local Medicare Coverage Determination was identified for GES; coverage may vary by contractor. Providers should check current Medicare policies and local coverage decisions when submitting claims or prior authorization requests.

No NCD or LCD found at time of review; coverage decisions may differ across jurisdictions.
Review applicable Medicare policy for the most up‑to‑date information prior to submission.

Note

Policy Review and Revision Note

Annual review on 11/15/2025 resulted in no clinical policy statement changes. Prior revision dates are noted in the policy history; providers should ensure they reference the current effective date when submitting prior authorization requests.

Annual review date: 11/15/2025 — no clinical policy statement changes.
Prior revision: 10/15/2023 (policy history).

TechniquesEndoscopic placement of temporary mucosal leads or percutaneous insertion of unipolar leads anchored to submucosal tissue (TPGES).

Regulatory noteFDA approval for temporary GES was not found; use of temporary external leads for GES represents off-label use.

DIAMOND / Tantalus device — investigational system description

Device descriptionDIAMOND (TANTALUS) consists of three pairs of bipolar electrodes attached to gastric fundus and antrum and connected to a rechargeable pulse generator implanted subcutaneously.

Developer / purposeDeveloped by MetaCure, Inc. for investigation in overweight/obese patients with type 2 diabetes mellitus.

ProgrammingDelivered electrical signal characteristics are set by a programmer within the first week after implantation; generator uses a rechargeable battery.

Transcend / Exilis / Enterra — examples of GES systems studied

Examples of systems studiedTranscend, Exilis, and Enterra have been studied as GES systems for obesity or gastroparesis.

Regulatory status for obesity indicationTranscend IGS and other systems are not FDA-approved for obesity; GES for obesity is registered by FDA as investigational.

Mechanistic uncertaintyMechanism for obesity treatment is unclear (possible enteric, autonomic, central or neurohormonal effects); optimal stimulation patterns and electrode placement remain undetermined.

Humanitarian Device Exemption (HDE) — regulatory designation reference (product code LNQ)

Regulatory designation nameHumanitarian Device Exemption (HDE)

FDA product codeLNQ

ImplicationHDE-listed devices are intended for conditions affecting fewer than 8,000 individuals annually and have distinct evidentiary requirements versus PMA/510(k).

Enterra Therapy — manufacturer and study references for treatment of refractory gastroparesis

Manufacturer(s)Enterra Therapy System: Medtronic, Inc. (Enterra II systems also listed with Enterra Medical, Inc. updates).

Clinical useReferenced as an implanted gastric electrical stimulation system used to treat chronic, intractable (drug-refractory) nausea and vomiting secondary to gastroparesis.

Supporting studies and referencesMultiple clinical studies and reviews cited (see references list; e.g., Maranki et al., Zoll et al., FDA HDE database entries).

HDE identifier and decision datesEnterra Therapy System H990014 (decision 3/31/2000); Enterra II supplements S105 (9/15/2015) and S227 MR conditional (10/20/2023).

Policy statement for gastric electrical stimulation (GES) or gastric pacing for any other indication was revised.

2009-?randomized trial (DIGEST/other)

Multiple RCTs and trials (including DIGEST and other early studies) reported variable short-term weight loss results with limitations in sample size and follow-up.

2009-?SHAPE trial (randomized)

SHAPE randomized, double-blinded, placebo-controlled trial (n=190) found no statistically significant excess weight loss at 12 months compared with control.

2014systematic review

Cha et al. systematic review (n=31 studies/1,367 patients) found short-term weight loss in many studies but overall low-quality evidence and inconsistent long-term maintenance.

2020phase 1 multicenter cohort

Paulus et al. multicenter, phase 1 open prospective cohort (Exilis system, n=20) reported safety but limited long-term weight loss (mean EWL ~14.2% at 52 weeks) and no significant differences in gastric emptying or metabolic measures between ON and OFF conditions.

2015-?case series for T2DM (DIAMOND)

Case series and early studies of devices such as the DIAMOND/TANTALUS for overweight/obese patients with T2DM reported preliminary improvements in glycemic control and weight but evidence is limited and RCTs are needed.